Stocks That Hit 52-Week Lows On Wednesday
During Wednesday's trading, 517 companies set new 52-week lows.
Truist Securities Maintains Buy on HOOKIPA Pharma, Lowers Price Target to $11
Truist Securities analyst Asthika Goonewardene maintains HOOKIPA Pharma (NASDAQ:HOOK) with a Buy and lowers the price target from $16 to $11.
SVB Leerink Maintains Outperform on HOOKIPA Pharma, Lowers Price Target to $3
SVB Leerink analyst Andrew Berens maintains HOOKIPA Pharma (NASDAQ:HOOK) with a Outperform and lowers the price target from $4 to $3.
HOOKIPA Pharma Q2 EPS $(0.23) Beats $(0.36) Estimate, Sales $2.75M Miss $3.56M Estimate
HOOKIPA Pharma (NASDAQ:HOOK) reported quarterly losses of $(0.23) per share which beat the analyst consensus estimate of $(0.36) by 36.11 percent. This is a 55.77 percent increase over losses of $(0.52) per share from
Earnings Scheduled For August 11, 2022
Companies Reporting Before The Bell
• Magic Software (NASDAQ:MGIC) is projected to report quarterly earnings at $0.27 per share on revenue of $131.70 million.
HOOKIPA Gets FDA Nod For Initial-Stage Prostate Cancer Study
The U.S. Food and Drug Administration (FDA) has accepted HOOKIPA Pharma’s (NASDAQ: HOOK) Investigational New Drug (IND) application for HB-300, a novel arenaviral immunotherapy for the treatment of metastatic castration-resistant prostate cancer.
HOOKIPA Pharma Announces FDA Accepts Co.’s Investigational New Drug Application For HB-300 For The Treatment Of Metastatic Castration-resistant Prostate Cancer
Novel arenaviral immunotherapy is directed against the prostate cancer targets PAP and PSA; Phase 1/2 trial to commence by early 2023
Drug Master File (DMF) accepted to support future FDA submissions